Introduction
Hypertension (HT) and diabetes mellitus (DM) are on the rise in industrialised nations because populations are ageing, and both increase with age. Frequently, HT is associated with DM and its prevalence doubles in diabetics compared to the general population. 1, 2 Many type II diabetics develop HT. This high prevalence is associated with increased stiffness of large arteries, which often precedes macrovascular events. 3, 4 The arterial system propagates pressure and flow waves at a certain velocity largely determined by the elastic properties of the arterial wall. 5 Aortic stiffness can be assessed noninvasively in large populations by measuring carotid-femoral pulse wave velocity (PWV), a simple and reproducible method. 6, 7 Several studies have shown significant interactions between PWV and the major cardiovascular risk factors, such as age, gender, HT, DM, smoking, and a close correlation with atherosclerosis. [8] [9] [10] In the presence of atherosclerotic lesions, a high carotid-femoral PWV was found even after adjustments on confounding factors. 10 Little is known about the effect of both high blood pressure (BP) and DM on aortic stiffness. [11] [12] [13] The aim of our study was to evaluate the influence of BP and type II DM on aortic stiffness in patients with one disease or the other compared to those with both HT and type II DM.
Methods

Study population
This investigation studied aortic stiffness in diabetic, hypertensive, and diabetic and hypertensive patients, who attended the outpatient HT clinic at the Second University of Naples between January and October 2002. We selected 185 patients, 50 with type II DM (Group A, mean age 5577 years, 34 men), 50 with HT (Group B, mean age 53710 years, 30 men) and 85 with type II DM and HT (Group C, mean age 5578 years, 33 men), for whom arterial stiffness measurements by PWV were available. A control group included 35 healthy subjects (HS, mean age 5277 years, 21 men). Participants had been diagnosed with DM and HT for at least 1 year (duration of both diseases: 7.671.5). The diagnosis of HT was considered when SBP was 4140 mmHg and/or DBP 490 mmHg and when antihypertensive therapy was present. BP was measured by a mercury sphygmomanometer with an appropriate size rubber cuff. Readings were based on Korotkoff first and fifth phase sounds. Three consecutive BP readings were obtained with the subject in supine position after a rest of at least 15 min. The average of the last two readings was used for the analyses, recorded to the nearest 2 mmHg on the scale. Measurements were performed early in the morning and carried out by a trained investigator.
Type II DM was defined as a fasting blood glucose level 4126 mg/dl (7.0 mmol/l), confirmed on a subsequent day, according to the report of the Expert Committee on the diagnosis and classification of DM, 14 or use of hypoglycaemic agents. None had any evidence or history of atherosclerotic disease, myocardial infarction, or stroke. Patients with cardiovascular conditions who can produce altered BP waveforms, including arrhythmias, valvular heart disease, or congestive heart failure, were excluded. Additional exclusions were being overweight, defined as a body mass index (BMI) 435 kg/m 2 and smoking more than 20 cigarettes per day. In the 4 h before the instrumental procedures, subjects were prohibited from eating, smoking, drinking coffee, or doing any heavy physical activity. All patients followed a diet with normal salt intake (3 g/day).
Among hypertensive patients, 61 subjects used antihypertensive drug therapy: ACE inhibitors (n ¼ 30), calcium antagonists (n ¼ 21), beta-blockers (n ¼ 5), diuretics (n ¼ 5); among diabetic patients, 80 were receiving hypoglycaemic agents: sulphamides (n ¼ 30), and/or biguanids (n ¼ 50). Pharmacological treatment was stopped 4 days before inclusion. Moreover, for each patient we evaluated clinical parameters such as age, sex, BMI, smoking habit, heart rate, pulse pressure (PP, defined as systolic BP minus diastolic BP), and mean BP (MBP, calculated as MBP ¼ DBP þ PP/3). We also determined lipid profile, uric acid, and fibrinogen in the serum. Venous blood samples were obtained after an overnight fast. Each subject provided informed consent for the study.
PMV measurement
Regional arterial stiffness was assessed by carotid-femoral PWV. The acquisition frequency of pressure waveforms was 500 Hz obtained by using two pressure transducers with a large-frequency bandwidth (TY-306; Fukuda Denshi Co., Tokyo, Japan) connected to an automatic processor (Complior s ; Colson AS, Paris, France). Assessment of arterial stiffness by PWV measurement is a standardised, repeatable and widely used method. 6 It is based on a simple technique, which consists of recording pressure waveforms at two different arterial sites: at the base of the neck for the common carotid artery and over the right femoral artery. The pulse transit time between the two recording sites is related to the distance between the two points of measurement. The on-line computerised measurements were analysed using an algorithm based on the time-shifted and repeated linear correlation calculation between the initial rise in the pressure waveforms. All measurements were performed, after 15 min of supine rest, by the same observer, who was blind to the BP of the subject. Since the biophysical properties of the aorta can vary on a short-term basis, possibly as a result of sympathetic activity, a minimum of 10 and a maximum of 22 measurements were performed and used for the calculation of the mean velocity. The inter-intraobserver reproducibility coefficients were 40.90, calculated in a sample of 35 normal subjects.
Statistical analysis
Statistical analysis was carried out by Stat View software (SAS Institute, Cary, NC, USA). Comparison among groups was performed using ANOVA plus Bonferroni's t-test for unpaired data. Bonferroni's correction was used to assess differences (P values p0.008 indicated significance). Comparisons of categorical data were made using Fisher's exact test. Stepwise forward regression analysis was performed to assess which factors independently influence PWV and was used to determine which variable was selected first. Variables selected for inclusion in the model were those significant at univariate analysis. Significance was defined as Po0.05. Table 1 shows the anthropometric characteristics and the haemodynamic parameters of the groups. There were no significant differences in age, BMI, and heart rate among the four groups. The hypertensive diabetic group had significantly more women and nonsmokers and the highest PP (61714 mmHg). Of the biochemical parameters, only fibrinogen was significantly higher in Group A and in Group C (Po0.01 and Po0.001, respectively). The highest PWV were observed in patients with hypertension and type II DM (Group C), showing a significant difference compared to the other groups (Po0.0001). Stepwise forward regression analysis (Table 2) showed that fasting glucose followed by MBP were independent predictors of PWV (Po0.0001). We introduced MBP into the model, rather than SBP/DBP and PP, because MBP is not directly dependent on arterial stiffness.
Results
Discussion
The main result of this study is that arterial stiffness, measured through PWV, was higher in patients with both DM and HT. The analysis showed the greater influence of DM on increasing arterial stiffness and that fasting glucose is the first independent determinant of PWV. Diabetics had a slightly higher PWV with a lower MBP than hypertensives and diabetic/hypertensive patients had a greatest PWV with no significant difference in MBP compared to hypertensives. The observed differences in PWV among groups cannot be attributed to other variables (such as age, BMI, and heart rate) since they were similar in all of them. However, the highly significant correlation between PWV and another risk factor, fasting glucose, suggests an underlying diffuse atherosclerosis involving large arteries.
Morbidity and mortality in diabetes are caused mainly by vascular complications in the microcirculation and large vessels, and consist of accelerated atherosclerosis. 3, 15, 16 Changes in arterial stiffness have been observed even at an early stage of disease and in young nondiabetic adults with a family history of type II DM. The prevention of micro-and macroangiopathy requires tight blood glucose control. 17 The results of several studies, analysing the effect of DM on the arterial wall, are heterogeneous despite a general tendency toward an increase of the arterial stiffness in diabetics. 18 The mechanism of increased arterial stiffness relates to changes in elastin and collagen within the walls; the elastin fibres become fractured and collagen deposition is increased. Moreover, high glucose levels promote the formation of advanced glycation end-products, which has been associated with changes in the vessel walls. On the other hand, the role of hyperglycaemia in the physiopathology of macroangiopathy remains controversial and the prevention of macrovascular events seems to involve the treatment of cardiovascular risk factors associated with DM, essentially HT. 19 There is strong evidence that in essential HT, the main change in vasculature resistance is a change in structure; the stiffness of arteries is strongly influenced by transmural distending pressure and hence by MBP. The prevalence of HT is at least twice as high in the diabetic population as in the background population. In type II DM, arterial HT plays an important role in the initiation and the progression of diabetic micro-macroangiopathy, and both are the most important risk factors for cardiovascular [20] [21] [22] These alterations modify physiological and mechanical properties of the arterial wall, which may become clinically evident by increasing PP, making it easier to establish the progression of atherosclerosis.
In our study, the highest value of PP in diabetic hypertensives may reflect already diseased arterial walls, with several adverse cardiac implications of potential prognostic value. 23, 24 PP arises from the interaction of cardiac ejection (stroke volume) and viscoelastic properties of large arteries. An increased stiffness of the aorta and large arteries leads to an increase in PP through a reduction in arterial compliance and a premature return of reflected waves in late systole, increasing the load on the ventricle and increasing myocardial oxygen demand. 25 These abnormalities can be attributed not only to the stretching effects of elevated BP but also to intrinsic alterations of the arterial wall, which could represent either adaptive structural and functional changes secondary to the chronic increase in BP, or primary abnormalities of the vessel wall. Local hormonal factors may play a role in the modification of the arterial wall, mainly by modifying cell growth or synthesis of the extracellular matrix. 26 Among these factors, angiotensin II may be of particular importance, since it induces hypertrophy of vascular smooth muscle cells in culture and increases collagen production by fibroblasts, mediated by the effects of this peptide on the AT1 receptors. 27, 28 These outcomes may be useful as additional factors in risk assessment for future therapeutic decision-making. Change in BP is a poor indicator of changing resistance in vessel structure. Although the effect on BP may be the same, trials have shown that antihypertensive treatments have different effects on the arterial wall. [29] [30] [31] A therapeutic strategy is not only able to reduce glycaemia, BP, and concomitant risk factors but also to reduce aortic stiffness, and may be an effective way to lower cardiovascular morbidity and mortality in hypertensive diabetics. Moreover, among risk factors, it is useful to underscore the importance of fibrinogen, a recognised marker of cardiovascular risk, which we observed to be significantly increased in diabetic patients with or without HT. This confirmed the well-known association between blood glucose and fibrinogen. 32 In conclusion, this study shows that patients with diabetes and HT have higher arterial stiffness compared to those with one disease or the other. Fasting glucose is the first independent determinant of PWV that may be used as a relevant tool to assess the influence of cardiovascular risk factors on arterial stiffness in high-risk patients.
